|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06833 SINCO PHARMA
Nominal 
0.185 -0.003 (-1.596%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 2,084,573 | -26.114% | 2,821,321 | 2,540,063 | 2,271,505 | 2,024,055 |
| Cost of Sales | (1,862,483) | -26.132% | (2,521,380) | (2,216,783) | (1,965,637) | (1,659,105) |
| Gross Profit | 222,090 | -25.955% | 299,941 | 323,280 | 305,868 | 364,950 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (4,922) | (3,000) | (2,354) | 164 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 48,259 | -51.214% | 98,920 | 99,881 | 99,292 | 167,387 | |
| Taxation | (13,407) | -76.427% | (56,875) | (57,529) | (29,830) | (32,304) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 34,852 | -17.108% | 42,045 | 42,352 | 69,462 | 135,083 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 29,915 | 184.120% | 10,529 | 8,467 | 15,911 | 27,851 |
| Depreciation & Amortisation | 25,581 | 4.434% | 24,495 | 16,319 | 11,356 | 6,699 |
| Directors' Emoluments | -- | -- | 10,729 | 9,384 | 4,872 | 3,121 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 1.700 | -19.048% | 2.100 | 2.000 | 3.400 | 7.800 |
| DPS (cts) | 0.147 | -- | 0.185 | 0.354 | 0.858 | 0.000 |
| Dividend Payout Ratio (%) | 8.632% | -- | 8.829% | 17.682% | 25.231% | -- |
| Cash flow per share ($) | -- | -- | (0.115) | 0.174 | 0.037 | 0.176 |
| NBV per share ($) | 0.341 | -- | 0.326 | 0.309 | 0.297 | 0.200 |
| Remarks: | Real time quote last updated: 02/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 34,852 |
| %Change | -17.108% |
| EPS / (LPS) | RMB 0.017 |
| NBV Per Share (¥) | RMB 0.341 |